[Factors limiting the correction of anemia with recombinant human erythropoietin]
- PMID: 1817332
[Factors limiting the correction of anemia with recombinant human erythropoietin]
Abstract
The efficacy of recombinant human erythropoietin in correcting the anemia of the uraemic patient has been thoroughly confirmed. Iron deficiency, aluminum intoxication, severe hyperparathyroidism and infections are some of the main factors limiting patients' response to the drug. Worsening or de novo formation of arterial hypertension generally makes it necessary to diminish the degree of correction of anaemia. It is commonly accepted that anaemia should be only partially corrected and that the target haemoglobin level should be defined patient by patient.
Similar articles
-
[Erythropoietin treatment in Piedmont and Valle d'Aosta].Minerva Urol Nefrol. 1991 Jul-Sep;43(3):143-5. Minerva Urol Nefrol. 1991. PMID: 1817336 Italian.
-
[Hemo-rheologic changes following treatment with human recombinant erythropoietin in chronic hemodialysis patients].Minerva Urol Nefrol. 1992 Apr-Jun;44(2):155-9. Minerva Urol Nefrol. 1992. PMID: 1411865 Italian.
-
Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.Haematologica. 1992 Nov-Dec;77(6):494-501. Haematologica. 1992. PMID: 1289186 Clinical Trial.
-
The role of erythropoietin and other growth factors in transfusion medicine.Transfus Med Rev. 1991 Jan;5(1):33-47. doi: 10.1016/s0887-7963(91)70191-0. Transfus Med Rev. 1991. PMID: 1802275 Review. No abstract available.
-
The adverse effects of recombinant human erythropoietin therapy.Adverse Drug React Acute Poisoning Rev. 1990 Winter;9(4):183-206. Adverse Drug React Acute Poisoning Rev. 1990. PMID: 2088088 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical